Blood Cell Ratios May Signal HFpEF Survival in the ICU
A study links certain blood cell ratios to 28-day mortality outcomes for patients with heart failure in intensive care.
Updated on Oct. 21, 2026 in Heart Disease
Live Poll
Should medical practitioners prioritize using existing routine blood tests to assess patient risk?
A retrospective study of 5,774 intensive care patients published October 21, 2026, suggests a link between certain blood cell ratios and survival in those with heart failure with preserved ejection fraction (HFpEF). Researchers identified that higher platelet-to-white blood cell ratios may correlate with a lower risk of death within 28 days of ICU admission.
Why it matters
Prognostic tools help clinicians better assess the risk of critical outcomes in HFpEF patients, where inflammatory stress often complicates care. This analysis provides a potential new metric for predicting patient survival during intensive care stays.
This retrospective analysis examined 5,774 patients using MIMIC-IV and eICU database information, observing 632 deaths within 28 days. While the model achieved an AUROC of 0.813, the clinical impact of adding this ratio to standard baseline models remains modest.
The details
The platelet-to-white blood cell ratio may serve as an indicator of the physiological balance between platelet availability and leukocyte-driven inflammatory stress. By analyzing blood measurements taken within 24 hours of ICU admission, researchers applied machine learning, including random forest models and Cox proportional hazards, to evaluate how this ratio associates with mortality. Patients in higher quartiles of this blood ratio showed reduced hazard ratios compared to the first quartile, suggesting a potential prognostic signal.
Timeline
24 hours: The window for initial blood measurements after ICU admission.
28 days: The total observation period for recording all-cause mortality.
Health Landscape
This research utilizes the MIMIC-IV database to advance the use of electronic health record data for identifying prognostic markers in intensive care. It builds upon established efforts to improve survival prediction for patients with heart failure with preserved ejection fraction.
This study is an analysis of critical care data and does not change your daily habits or individual treatment plan. If you or a loved one are managing HFpEF, discuss any concerns regarding prognosis or blood work results with a cardiologist or critical care physician.
The takeaway
While this ratio shows promise for helping doctors assess mortality risk in intensive care, it remains a tool for clinical research rather than a diagnostic standard. Discuss your specific heart failure management and any concerns about blood markers with your primary care provider or specialist.
Further reading
For broader context on managing cardiovascular health, visit our section on Heart Disease.
Source note: This article includes information reported by Nature.
Live Poll
Should medical practitioners prioritize using existing routine blood tests to assess patient risk?
